IP Library Granted Patent US 10,287,631
Granted Patent B2
US 10,287,631 · App. 15/660,785 · Granted May 14, 2019

Methods of lowering the error rate of massively parallel DNA sequencing using duplex consensus sequencing

Inventors: Jesse Salk (Seattle, WA); Lawrence A. Loeb (Bellevue, WA); Michael Schmitt (Seattle, WA)
Assignee: UNIVERSITY OF WASHINGTON THROUGH ITS CENTER FOR COMMERCIALIZATION
C12Q1/6876C12Q1/6806C12Q1/6869
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,287,631
App. No.
15/660,785
Granted
May 14, 2019
Kind
B2
Abstract

Next Generation DNA sequencing promises to revolutionize clinical medicine and basic research. However, while this technology has the capacity to generate hundreds of billions of nucleotides of DNA sequence in a single experiment, the error rate of approximately 1% results in hundreds of millions of sequencing mistakes. These scattered errors can be tolerated in some applications but become extremely problematic when “deep sequencing” genetically heterogeneous mixtures, such as tumors or mixed microbial populations. To overcome limitations in sequencing accuracy, a method Duplex Consensus Sequencing (DCS) is provided. This approach greatly reduces errors by independently tagging and sequencing each of the two strands of a DNA duplex. As the two strands are complementary, true mutations are found at the same position in both strands. In contrast, PCR or sequencing errors will result in errors in only one strand.

Claims (52)

1. A method of generating high accuracy sequence reads of a population of double-stranded target nucleic acid molecules, comprising:

ligating each of the double-stranded target nucleic acid molecules to at least one adapter molecule, to form a population of adapter-target nucleic acid complexes, wherein each of the adapter molecules comprises—

(a) a degenerate or semi-degenerate single molecule identifier (SMI) sequence that alone or in combination with the target nucleic acid fragment ends uniquely labels each ligated double-stranded target nucleic acid molecule such that each ligated double-stranded target nucleic acid molecule is distinguishable from other ligated double-stranded target nucleic acid molecules in the population, and

(b) a strand-distinguishing nucleotide sequence that, following the ligation step, provides a region of non-complementarity between a first strand of each adapter-target nucleic acid complex and a second strand of the same adapter-target nucleic acid complex;

for each of the adapter-target nucleic acid complexes—

amplifying each strand of the adapter-target nucleic acid complex to produce a plurality of first strand adapter-target nucleic acid complex amplicons and a plurality of second strand adapter-target nucleic acid complex amplicons;

sequencing the adapter-target nucleic acid complex amplicons to produce a plurality of first strand sequence reads and plurality of second strand sequence reads;

grouping the first strand sequence reads and the second strand sequence reads into a family of first and second strand sequence reads based on the degenerate or semi-degenerate SMI sequence alone or in combination with the target nucleic acid fragment ends;

separating the first and second strand sequence reads into a set of first strand sequence reads and a set of second strand sequence reads based on the region of non-complementarity between the first strand and the second strand of the adapter-target nucleic acid complex;

confirming the presence of at least one first strand sequence read and at least one second strand sequence read;

comparing the at least one first strand sequence read with the at least one second strand sequence read;

identifying nucleotide positions where the compared first and second strand sequence reads are non-complementary;

identifying nucleotide positions where the compared first and second strand sequence reads are complementary; and

generating a high accuracy consensus sequence read for each of the double-stranded target nucleic acid molecules in the population that includes only the nucleotide positions where the compared first and second strand sequence reads are complementary.

2. The method of claim 1 , wherein the confirming step includes confirming the presence of at least 2 first strand sequence reads and at least 2 second strand sequence reads.

3. The method of claim 1 , further comprising identifying one or more nucleotide positions that disagree between the at least one first strand sequence read and the at least one second strand sequence read.

4. The method of claim 1 , wherein for any double-stranded target nucleic acid molecule in the population, the method further comprises:

comparing the high accuracy consensus sequence read to a respective reference sequence; and

identifying one or more nucleotide sequence variations present in the high accuracy consensus sequence read not present in the reference sequence.

5. The method of claim 4 , further comprising identifying a variation occurring at a particular position in the high accuracy consensus sequence read as a true mutation.

6. The method of claim 4 , further comprising identifying a variation that occurs at a particular position in only one of the first strand sequence read or the second strand sequence read as a potential artifact.

7. The method of claim 1 , wherein for any double-stranded target nucleic acid molecule in the population, the method further comprises:

comparing the high accuracy consensus sequence read to a reference sequence;

identifying one or more variations present in the high accuracy consensus sequence read not present in the reference sequence; and

identifying at least one of a cancer, a cancer risk, a cancer metabolic state, a mutator phenotype, a carcinogen exposure, a chronic inflammation exposure, an age, a neurodegenerative disease, or a combination thereof in an organism from which the double-stranded target nucleic acid molecule is derived by the one or more variations present in the high accuracy consensus sequence read.

8. The method of claim 1 , wherein the population of double-stranded target nucleic acid molecules includes double-stranded DNA or other nucleic acid fragments.

9. The method of claim 1 , wherein each of the adapter-target nucleic acid complexes comprises at least two primer binding sites.

10. The method of claim 1 , wherein the adapter molecule ligated to any particular double-stranded target nucleic acid molecule comprises a Y-shape, a U-shape, or a combination thereof.

11. The method of claim 1 , wherein the population of adapter-target nucleic acid complexes comprise an SMI sequence in each of its strands.

12. The method of claim 1 , wherein each adapter molecule comprises a double-stranded SMI sequence, and wherein the double-stranded SMI sequence comprises a first degenerate or semi-degenerate sequence and a second degenerate or semi-degenerate sequence.

13. The method of claim 12 , wherein the first and second degenerate or semi-degenerate sequences are at least partially complementary.

14. The method of claim 1 , wherein the population of adapter-target nucleic acid complexes comprise an SMI sequence at each terminus.

15. The method of claim 1 , wherein the degenerate or semi-degenerate SMI sequence comprises from about 3 to about 20 nucleotides.

16. A method of generating high accuracy sequence reads of a population of double-stranded target nucleic acid molecules, wherein each individual double-stranded target nucleic acid molecule comprises one or more fragment features that distinguish the individual double-stranded target nucleic acid molecules from other double-stranded target nucleic acid molecules in the population, the method comprising:

ligating each of the double-stranded target nucleic acid molecules to at least one double-stranded adapter molecule, to form an adapter-target nucleic acid complex, wherein—

the at least one double-stranded adapter molecule comprises a region of non-complementarity between a first adapter strand of the double-stranded adapter molecule and a second adapter strand of the double-stranded adapter molecule, and

following the ligation step, the region of non-complementarity provides a strand-distinguishing nucleotide sequence such that a first strand of the adapter-target nucleic acid complex has a distinctly identifiable nucleotide sequence relative to its complementary second strand;

for each of the adapter-target nucleic acid complexes—

amplifying each strand of the adapter-target nucleic acid complex to produce a plurality of first strand adapter-target nucleic acid complex amplicons and a plurality of second strand adapter-target nucleic acid complex amplicons;

sequencing the adapter-target nucleic acid complex amplicons to produce a plurality of first strand sequence reads and plurality of second strand sequence reads;

grouping the first and second strand sequence reads into a family of sequence reads by identifying the one or more distinguishing fragment features shared by each strand of the double-stranded target nucleic acid molecule;

separating the first and second sequence reads from each family into a set of first strand sequence reads and a set of second strand sequence reads based on the strand-distinguishing nucleotide sequence;

confirming the presence of at least one first strand sequence read and at least one second strand sequence read;

comparing the at least one first strand sequence read with the at least one second strand sequence read; and

generating a high accuracy consensus sequence read for each of the double-stranded target nucleic acid molecules in the population that includes only the nucleotide positions where the compared first and second strand sequence reads are complementary.

17. The method of claim 16 , wherein the double-stranded target nucleic acid molecule is a double-stranded DNA or other nucleic acid fragment.

18. The method of claim 16 , wherein the one or more fragment features includes a shear point or other fragment region, or a combination thereof.

19. The method of claim 16 , wherein the adapter-target nucleic acid complex comprises at least two primer binding sites.

20. The method of claim 16 , wherein the adapter-target nucleic acid complex comprises a Y-shape, a U-shape, or a combination thereof.

21. The method of claim 16 , wherein generating a high accuracy consensus sequence further comprises identifying nucleotide positions where the compared first and second strand sequence reads are non-complementary and scoring the identified non-complementary nucleotide positions as potential artifacts.

22. The method of claim 1 , wherein each adapter molecule comprises a single stranded SMI sequence, and wherein the method further comprises converting the single-stranded SMI sequence to a double-stranded SMI sequence by polymerase extension.

23. The method of claim 1 , wherein generating a high accuracy consensus sequence further comprises marking the identified nucleotide positions where the compared first and second strand sequence reads are non-complementary and scoring the identified non-complementary nucleotide positions as potential artifacts.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 26, 2019
From: SALK, JESSE; LOEB, LAWRENCE A.; SCHMITT, MICHAEL
To: UNIVERSITY OF WASHINGTON THROUGH ITS CENTER FOR COMMERCIALIZATION
Reel/Frame 048706/0919 →
Continuity (5)
Continuation 14386800
Provisional Application 61613413 · Mar 20, 2012
Provisional Application 61625623 · Apr 17, 2012
Provisional Application 61625319 · Apr 17, 2012
Related Publication 20180142293A1 · May 24, 2018
Cited By (19)
US 12,241,123 US 12,252,749 US 12,258,626 US 12,258,629 US 12,281,354 US 12,286,672 US 12,319,961 US 12,319,972 US 12,435,368 US 12,529,101 US 12,534,751 US 12,540,350 US 12,540,355 US 12,577,617 US 12,606,874 US 12,624,400 US 12,662,697 US 12,680,131 US 12,692,554